Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 10/26/11, any daily gain at risk by next day

The 6 W’s: Who, what, where, when, why and what of it …

 

Warren Buffett often says when others are afraid, buy and when they are euphoric, sell. I believe this is the time when excess pessimism has negatively impacted investors’ perspectives about the reality of earnings growth. Don’t get caught up in this negative spiral psychological game (just like you want to avoid the optimism trap as well).

Receiving, disseminating and digesting …information on a rational basis will unfold … advantage  and opportunity … as they present themselves even if the mood is .. gloomy or overly euphoric. Rational and informed investors will be rewarded … that, is why … I provide this … focused … MESSAGING!

 

Mid-Day: The NASDAQ is Down -12.92 (-0.49%) to 2,625.50. The Dow is UP +43.14 (+0.37%) to 11,749.76.

 

Mid-Day Movers: BioTime (AMEX: BTX), Cytori (NASDAQ:CYTX), Geron (NASDAQ:GERN),  Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (NASDAQ:KOOL)

 

 What’s new in the regenerative medicine/stem cell market …

Venture Capitalists Put Money on Easing Medical Device Rules: http://www.nytimes.com/2011/10/26/business/venture-capitalists-join-push-to-ease-fda-rules-for-medical-device-industry.html?hp

 

TiGenix (NYSE Euronext: TIG) P2a Rheumatoid Arthritis Trial: received the go-ahead from the independent Safety Monitoring Board to move into the randomized stage of the P2a clinical trial in rheumatoid arthritis (Cx611). This decision is based on the analysis of the safety data from patients treated in the study’s 1st cohort. The bottom line, the objective of the PIb/IIa trial is to determine safety, feasibility, tolerance, and optimal dosing. This multicentre, placebo-controlled study will involve approximately 53 patients, divided in 3 cohorts with different dosing regimens. There are more than 20 centers open and TIG expects the final results to be available in the first half of 2013. http://www.scimitarequity.com/blog/2011/10/25/tigenix-nyse-euronext-tig-p2a-rheumatoid-arthritis-trial

 

NIH director supports streamlining the drug approval process:  Francis Collins voiced his commitment to smoothing the path in the approval process for new drugs during a presentation on Monday at the American Association of Pharmaceutical Scientists annual meeting. The bottom line, Collins said NIH should take an “engineering approach” to removing bottlenecks and reported that NIH backs the establishment of a National Center for Advancing Translational Sciences to streamline development of new medicines.

 

EU ban on ESC patents might speed up research:  The European Court of Justice’s retroactive ban on patents for procedures involving the destruction of a human embryo might speed innovation as companies’ instead patent technologies, chemicals, equipment and growth media for turning embryonic stem cells into treatments, experts say. “If anything the ruling is an opportunity,” said scientist Chris Mason of University College London …… food for thought??http://www.nature.com/news/2011/111024/full/478441a.html

 

Novartis AG (NYSE:NVS) to Cut 2000 Swiss, U.S. Jobs, Add Positions in China and India:  to offset the effect of drug-price reductions. The bottom line, the cuts, equal to 1% of Novartis’s workforce, will be implemented over three to five years, and will generate annual savings of more than $200M. Novartis will close a plant in Nyon, Switzerland, that makes over-the- counter drugs, and chemical sites in Basel and Torre, Italy, and plans a Q4 charge of about $300M. CE Joe Jimenez has been reducing costs since he took the top job 2/10. Government austerity measures in Europe have forced Novartis to lower prices by about 5% this year, he said on a call with reporters as the company announced that third-quarter profit rose 12%. (BioSpace)

 

Cytori (CYTX) to Webcast Q3/11 Financial Results: http://www.scimitarequity.com/blog/2011/10/26/cytori-cytx-to-webcast-q311-financial-results

 

FDA Commissioner Margaret Hamburg recently introduced a 40-page blueprint for reform, telling the audience at the 3rd Annual Washington Ideas Forum that “the number of new products in the development pipeline is not where we’d like it to be.” http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm274333.htm

 

Group of microRNAs inhibits cell reprogramming: A group of microRNAs called miR-34 miRNAs inhibits cell reprogramming by blocking genes that play a role in pluripotency, according to a study published in Nature Cell Biology. The bottom line, the findings indicate that inhibiting miR-34 miRNAs may facilitate the transformation of somatic cells into induced pluripotent stem cells. http://the-scientist.com/2011/10/24/micrornas-prevent-cell-reprogramming